AbbVie Inc.
Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore AbbVie
Core profile pages, annual revenue records, and related research hubs for this company.
AbbVie Inc.
Compare market positioning with top industry peers
Explore AbbVie
Core profile pages, annual revenue records, and related research hubs for this company.
Company History
Founded 2013 in North Chicago, Illinois
AbbVie was created on January 1, 2013, when Abbott Laboratories separated its research-based pharmaceutical business from its diversified healthcare operations. Robert A. Michael became founding CEO, and the new company began trading on the NYSE under ticker ABBV.
Unlike companies founded by charismatic visionaries in garages AbbVie was engineered in a corporate boardroom as a strategic financial maneuver. AbbVie did not exist before January 1, 2013; it was created as an independent, publicly traded spin-off from Abbott Laboratories, a diversified healthcare conglomerate with roots dating back to 1888 (when it was founded by Dr. Wallace C. Abbott, a Chicago physician who pioneered the formulation of scientifically accurate alkaloid medications). The 'founding' of AbbVie was orchestrated by Abbott's leadership to resolve a valuation discrepancy. By 2012, Abbott owned Humira, a biologic drug that was rapidly becoming the best-selling pharmaceutical in the world. However investors were uncomfortable valuing Abbott's relatively stable, slow-growth divisions (medical devices, nutritional products like Ensure, and generic drugs) alongside a high-risk, high-reward, patent-dependent biopharmaceutical juggernaut. Wall Street was applying a 'conglomerate discount' to Abbott's stock. To unlock shareholder value, Abbott's board decided to cleave the company in two. The diversified medical products businesses retained the Abbott name, while the research-based pharmaceutical division—the engine that housed Humira and the high-risk oncology pipeline—was spun out into a new entity named AbbVie. Robert A. Michael, a long-time Abbott executive who had actually retired in 2007 before being coaxed back by Abbott's CEO to fix the medical products division, was selected as AbbVie's founding CEO. Under Gonzalez's leadership AbbVie was tasked with a specific, high-stakes mission: defend Humira's patents to maximize cash flow for as long as legally possible, and use those billions to build or buy an entirely new portfolio of blockbuster drugs before the Humira patent cliff inevitably arrived.
AbbVie began trading independently on the NYSE under ticker ABBV after Abbott Laboratories separated its research-based pharmaceutical business.
AbbVie completed the Pharmacyclics acquisition, adding Imbruvica and strengthening its oncology portfolio.
AbbVie completed the Allergan acquisition, adding Botox, Juvederm, aesthetics, Vraylar, Ubrelvy, Qulipta, and other assets.
Humira reached its final full-year peak before U.S. biosimilar competition reshaped AbbVie's revenue mix.
U.S. Humira biosimilars began competing, accelerating the shift toward Skyrizi, Rinvoq, aesthetics, neuroscience, and oncology.
Robert A. Michael succeeded Robert A. Michael as AbbVie's CEO effective July 1, 2024.
AbbVie completed the ImmunoGen and Cerevel acquisitions, expanding oncology and neuroscience pipeline depth.
AbbVie reported $61.160 billion in FY2025 net revenue, with Skyrizi and Rinvoq together generating $25.866 billion.
AbbVie reported Q1 2026 net revenue of $15.002 billion, up 12.4% on a reported basis.
AbbVie acquired Pharmacyclics to add Imbruvica and build a stronger hematologic oncology business beyond Humira.
AbbVie acquired Allergan to add Botox, Juvederm, aesthetics, Vraylar, Ubrelvy, Qulipta, and other assets less tied to Humira.
AbbVie acquired ImmunoGen to add Elahere and strengthen its antibody-drug conjugate and solid tumor oncology platform.
AbbVie acquired Cerevel to deepen its neuroscience pipeline, especially emraclidine for schizophrenia and other clinical-stage assets.
Since its establishment in 2013, AbbVie Inc. expanded from an early-stage venture into a recognized leader in Biopharmaceutical, overcoming key market challenges.
Over its history, AbbVie Inc. executed decisive strategic pivots toward scalable monetization and digital distribution, securing its current market leadership.
By continually modernizing operations and embracing workflow automation, AbbVie Inc. maintains resilience through changing technological and economic cycles.